Study of ICP-248 for relapsed or refractory B-cell cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase (Phase 1) study tests ICP-248 in people with certain B-cell cancers that have come back (relapsed) or did not respond to prior treatment (refractory). The goal is to learn the safest dose and whether it can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 to 80.
- You have a confirmed B-cell cancer such as CLL/SLL, mantle cell lymphoma, or certain types of B-cell non-Hodgkin lymphoma (DLBCL, follicular, marginal zone, or lymphoplasmacytic).
- Your cancer has relapsed or is refractory, and you’re considered to need treatment (especially for CLL/SLL).
- You have enough measurable disease (for B-NHL) and you can have lab values showing adequate bone marrow, liver, kidney, heart, and lung function.
- You can do daily activities fairly well (ECOG score 0–2) and you’re expected to live at least 6 months.
- If you could become pregnant, you must have a negative pregnancy test and agree to reliable birth control through the study period and for 90 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new oral medications (ICP-248 and Orelabrutinib) together as a first treatment for people with CLL or SLL. The goal is to see if this combination works better than current options and is safe for newly diagnosed patients.
This trial tests a new drug called ICP-248 for people with mantle cell lymphoma that has returned or not responded to previous treatments. It aims to see if the drug is safe and effective.
This study compares two oral targeted therapies (ICP-248 plus orelabrutinib vs. pirtobrutinib) for people with mantle cell lymphoma that has returned or stopped responding to treatment. It aims to see which combination works better.
This trial tests an experimental drug (ICP-248) alone or with another antibody therapy for people with B-cell lymphomas that have returned or not responded to treatment. It aims to see if the drug is safe and if it can shrink or control the cancer.
This trial tests an investigational drug called ICP-490 for people with non-Hodgkin lymphoma that has come back or hasn't improved after prior treatments. The study checks if the drug is safe, tolerable, and effective.
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.